Literature DB >> 15521084

Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.

M Al-Aloul1, H Miller, S Alapati, P A Stockton, M J Ledson, M J Walshaw.   

Abstract

Although there are reports of cases of acute renal failure occurring in cystic fibrosis (CF) patients, usually in association with the use of nephrotoxic antibiotic therapy, there have been no studies of renal function in this patient group. We hypothesized that long-term use of intravenous (IV) nephrotoxic antibiotics (aminoglycosides and colistin sulphomethate) may contribute to renal disease in CF patients. In a prospective study, we assessed creatinine clearance as an index of renal function with two techniques (24-hr urine collections and the Cockroft-Gault formula) in a group of 80 stable adult CF outpatients chronically infected with Pseudomonas aeruginosa but with no history of preceding renal disease. Using a multiple linear regression model, we evaluated their renal function in terms of their lifetime IV use of aminoglycosides and colistin. Between 31% (Cockroft-Gault formula method) and 42% (24-hr urine collection method) of patients had a creatinine clearance below normal range. Using either method, there was a strong correlation between aminoglycoside use and diminishing renal function (r=- 0.32, P=0.0055), which was potentiated by the coadministration of colistin (r=- 0.42, P <0.0002). However, there was no correlation with colistin when used in combination with other antibiotics alone (r=0.18, P=NS). Repeated IV aminoglycoside use in CF is associated with long-term renal damage. Although this effect is potentiated by colistin, colistin on its own in moderate doses does not appear to be nephrotoxic. IV aminoglycosides should be used cautiously in CF patients, with regular monitoring of renal function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15521084     DOI: 10.1002/ppul.20138

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  41 in total

1.  Minimizing the toxicity of aminoglycosides in cystic fibrosis.

Authors:  Alan R Smyth
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Acute renal failure in people with cystic fibrosis.

Authors:  Kevin W Southern
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

3.  Routine OGTT screening for CFRD - no thanks.

Authors:  Martin Walshaw
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

4.  Colistin: the phoenix arises.

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

5.  Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients.

Authors:  Barbara O M Claus; Sylvia Snauwaert; Filomeen Haerynck; Sabine Van Daele; Frans De Baets; Petra Schelstraete
Journal:  Int J Clin Pharm       Date:  2015-05-23

6.  Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Authors:  Michael A Barras; David Serisier; Stefanie Hennig; Katrina Jess; Ross L G Norris
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

7.  Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis.

Authors:  Kevin J Downes; Neha R Patil; Marepalli B Rao; Rajesh Koralkar; William T Harris; John P Clancy; Stuart L Goldstein; David J Askenazi
Journal:  Pediatr Nephrol       Date:  2015-04-26       Impact factor: 3.714

Review 8.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 9.  Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.

Authors:  Andrew Prayle; Alan Watson; Heather Fortnum; Alan Smyth
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

10.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.

Authors:  David L MacLeod; Lynn M Barker; Jennifer L Sutherland; Suzanne C Moss; Jesse L Gurgel; Thomas F Kenney; Jane L Burns; William R Baker
Journal:  J Antimicrob Chemother       Date:  2009-08-13       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.